These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
112 related articles for article (PubMed ID: 6546602)
1. Combination chemotherapy with vincristine (NSC-67574), procarbazine (NSC-77213), prednisone (NSC-10023) with or without nitrogen mustard (NSC-762)(MOPP vs OPP) in children with recurrent brain tumors. Cangir A; Ragab AH; Steuber P; Land VJ; Berry DH; Krischer JP Med Pediatr Oncol; 1984; 12(1):1-3. PubMed ID: 6546602 [TBL] [Abstract][Full Text] [Related]
2. MOPP regimen as primary chemotherapy for brain tumors in infants. van Eys J; Cangir A; Coody D; Smith B J Neurooncol; 1985; 3(3):237-43. PubMed ID: 3840526 [TBL] [Abstract][Full Text] [Related]
4. MOPP chemotherapy without irradiation as primary postsurgical therapy for brain tumors in infants and young children. Ater JL; van Eys J; Woo SY; Moore B; Copeland DR; Bruner J J Neurooncol; 1997 May; 32(3):243-52. PubMed ID: 9049886 [TBL] [Abstract][Full Text] [Related]
5. [Combination chemotherapy with MOPP and intrathecal methotrexate in children with brain tumors]. Sato J; Ninomiya T; Saijo T; Akita H; Miki Y; Hirose M; Hashimoto T; Miyao M; Matsumoto K Gan To Kagaku Ryoho; 1986 Oct; 13(11):3266-70. PubMed ID: 3777962 [TBL] [Abstract][Full Text] [Related]
6. Therapy-related myelodysplastic syndrome in children with medulloblastoma following MOPP chemotherapy. Hayani A; Mahoney DH; Taylor LD J Neurooncol; 1992 Sep; 14(1):57-62. PubMed ID: 1469465 [TBL] [Abstract][Full Text] [Related]
7. Can MOPP be replaced in the treatment of advanced Hodgkin's disease? Canellos GP Semin Oncol; 1990 Feb; 17(1 Suppl 2):2-6. PubMed ID: 1689509 [TBL] [Abstract][Full Text] [Related]
8. Nitrogen mustard, vincristine, procarbazine, and prednisone as adjuvant chemotherapy in the treatment of medulloblastoma. A Pediatric Oncology Group study. Krischer JP; Ragab AH; Kun L; Kim TH; Laurent JP; Boyett JM; Cornell CJ; Link M; Luthy AR; Camitta B J Neurosurg; 1991 Jun; 74(6):905-9. PubMed ID: 2033450 [TBL] [Abstract][Full Text] [Related]
9. Randomized study for the treatment of adult advanced Hodgkin's disease: mechlorethamine, vincristine, procarbazine, and prednisone (MOPP) versus lomustine, vinblastine, and prednisone. Liebman HA; Hum GJ; Sheehan WW; Ryden VM; Bateman JR Cancer Treat Rep; 1983 May; 67(5):413-9. PubMed ID: 6342771 [TBL] [Abstract][Full Text] [Related]
10. BCVPP chemotherapy for advanced Hodgkin's disease: evidence for greater duration of complete remission, greater survival, and less toxicity than with a MOPP regimen. Results of the Eastern Cooperative Oncology Group study. Bakemeier RF; Anderson JR; Costello W; Rosner G; Horton J; Glick JH; Hines JD; Berard CW; DeVita VT Ann Intern Med; 1984 Oct; 101(4):447-56. PubMed ID: 6089632 [TBL] [Abstract][Full Text] [Related]
12. Combination chemotherapy with MOPP in children with recurrent brain tumors. Cangir A; van Eys J; Berry DH; Hvizdala E; Morgan SK Med Pediatr Oncol; 1978; 4(3):253-61. PubMed ID: 683129 [TBL] [Abstract][Full Text] [Related]
13. Treatment of advanced-stage massive mediastinal Hodgkin's disease: the case for combined modality treatment. Longo DL; Russo A; Duffey PL; Hubbard SM; Glatstein E; Hill JB; Jaffe ES; Young RC; DeVita VT J Clin Oncol; 1991 Feb; 9(2):227-35. PubMed ID: 1988570 [TBL] [Abstract][Full Text] [Related]
14. Treatment of advanced Hodgkin's disease with chemotherapy--comparison of MOPP/ABV hybrid regimen with alternating courses of MOPP and ABVD: a report from the National Cancer Institute of Canada clinical trials group. Connors JM; Klimo P; Adams G; Burns BF; Cooper I; Meyer RM; O'Reilly SE; Pater J; Quirt I; Sadura A; Shustik C; Skillings J; Sutcliffe S; Verma S; Yoshida S; Zee B J Clin Oncol; 1997 Apr; 15(4):1638-45. PubMed ID: 9193364 [TBL] [Abstract][Full Text] [Related]
15. Radiation therapy versus combination chemotherapy in the treatment of early-stage Hodgkin's disease: seven-year results of a prospective randomized trial. Longo DL; Glatstein E; Duffey PL; Young RC; Hubbard SM; Urba WJ; Wesley MN; Raubitschek A; Jaffe ES; Wiernik PH J Clin Oncol; 1991 Jun; 9(6):906-17. PubMed ID: 2033427 [TBL] [Abstract][Full Text] [Related]
16. Treatment of advanced-stage Hodgkin's disease: alternating noncrossresistant MOPP/CABS is not superior to MOPP. Longo DL; Duffey PL; DeVita VT; Wiernik PH; Hubbard SM; Phares JC; Bastian AW; Jaffe ES; Young RC J Clin Oncol; 1991 Aug; 9(8):1409-20. PubMed ID: 1712836 [TBL] [Abstract][Full Text] [Related]
17. Etoposide, vinblastine, and doxorubicin: an active regimen for the treatment of Hodgkin's disease in relapse following MOPP. Cancer and Leukemia Group B. Canellos GP; Petroni GR; Barcos M; Duggan DB; Peterson BA J Clin Oncol; 1995 Aug; 13(8):2005-11. PubMed ID: 7636541 [TBL] [Abstract][Full Text] [Related]
18. A comparative study of a BCNU containing 4-drug program versus MOPP versus 3-drug combinations in advanced Hodgkin's disease: a cooperative study by the Cancer and Leukemia Group B. Nissen NI; Pajak TF; Glidewell O; Pedersen-Bjergaard J; Stutzman L; Falkson G; Cuttner J; Blom J; Leone L; Sawitsky A; Coleman M; Haurani F; Spurr CL; Harley JB; Seligman B; Cornell C; Henry P; Senn HJ; Brunner K; Martz G; Maurice P; Bank A; Shapiro L; James GW; Holland JF Cancer; 1979 Jan; 43(1):31-40. PubMed ID: 367570 [TBL] [Abstract][Full Text] [Related]
19. A randomized study in stage IIIB and IV Hodgkin's disease comparing eight courses of MOPP versus an alteration of MOPP with ABVD: a European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group and Groupe Pierre-et-Marie-Curie controlled clinical trial. Somers R; Carde P; Henry-Amar M; Tarayre M; Thomas J; Hagenbeek A; Monconduit M; de Pauw BE; Breed WP; Verdonck L J Clin Oncol; 1994 Feb; 12(2):279-87. PubMed ID: 7509381 [TBL] [Abstract][Full Text] [Related]